Gene Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Gene Symbol AXL
Synonyms ARK | JTK11 | Tyro7 | UFO
Gene Description AXL, AXL receptor tyrosine kinase, is a receptor tyrosine kinase, which promotes growth, migration, and survival of tumor cells through activation of Mapk signaling (PMID: 28072762). Activation and overexpression of AXL has been associated with resistance to chemotherapeutic agents and targeted therapies (PMID: 28251492), in both solid and hematological tumors (PMID: 32148495).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
AXL A273V lung non-small cell carcinoma predicted - resistant Erlotinib Preclinical - Cell culture Actionable In a preclinical study, expression of AXL A273V in non-small cell lung cancer cells conferred resistance to Tarceva (erlotinib) in culture (Cancer Res 2018;78(13 Suppl): nr 4903). detail...
AXL amp lung non-small cell carcinoma predicted - sensitive Glesatinib Phase I Actionable In a Phase I trial, a patient with non-small cell lung carcinoma harboring AXL amplification was sensitive to treatment with Glesatinib (MGCD265), demonstrating a 50% decrease in lesion size (PMID: 26555154). 26555154
AXL negative head and neck squamous cell carcinoma decreased response Bemcentinib Preclinical Actionable In a preclinical study, Bemcentinib (BGB-324) did not inhibit proliferation or invasion of AXL-negative head and neck squamous cell carcinoma cell lines in culture (PMID: 25767293). 25767293
AXL over exp prostate cancer sensitive Bemcentinib + Metformin Preclinical Actionable In a preclinical study, Bemcentinib (BGB-324) and Glucophage (metformin) worked synergistically to inhibit growth of metformin-resistant prostate cancer cell lines harboring elevated Axl protein level in culture (PMID: 26036314). 26036314
AXL over exp prostate cancer sensitive Bemcentinib Preclinical Actionable In a preclinical study, Bemcentinib (BGB-324) inhibited growth of prostate cancer cell lines harboring elevated Axl protein level in culture (PMID: 26036314). 26036314
AXL over exp head and neck cancer sensitive Bemcentinib + Erlotinib Preclinical Actionable In a preclinical study, Bemcentinib (BGB-324) reverted acquired Tarceva (erlotinib)-resistance in head and neck cancer cell lines over expressing Axl and inhibited cell growth in culture (PMID: 24026012). 24026012
AXL over exp lung non-small cell carcinoma predicted - sensitive SGI-7079 Preclinical - Cell line xenograft Actionable In a preclinical study, SGI-7079 inhibited growth of mesenchymal non-small cell lung cancer cell lines expressing high levels of AXL in culture and reduced tumor growth in xenograft models (PMID: 23091115). 23091115
AXL over exp Advanced Solid Tumor sensitive RXDX-106 Preclinical - Cell line xenograft Actionable In a preclinical study, RXDX-106 inhibited Tam-family kinases activity in transformed cells over expressing Axl in culture, resulted in tumor growth inhibition in cell line xenograft models (Eur J Cancer, Vol 69, Supplement 1, December 2016, Page S31). detail...
AXL over exp triple-receptor negative breast cancer sensitive 20G7-D9 Preclinical - Pdx Actionable In a preclinical study, 20G7-D9 inhibited migration and invasion of triple-negative breast cancer (TNBC) cell lines with high expression of AXL in culture, and inhibited tumor growth in TNBC cell line and patient-derived xenograft models with high AXL expression levels (PMID: 27923843). 27923843
AXL over exp head and neck squamous cell carcinoma resistant Cetuximab Preclinical - Cell line xenograft Actionable In a preclinical study, Erbitux (cetuximab) treatment did not decrease proliferation of head and neck squamous cell carcinoma cells overexpressing AXL in culture, and did not inhibit tumor growth in a cell line xenograft model (PMID: 32439698). 32439698
AXL over exp head and neck squamous cell carcinoma sensitive Bemcentinib + Cetuximab Preclinical - Cell culture Actionable In a preclinical study, Bemcentinib (BGB-324) treatment in combination with Erbitux (cetuximab) synergistically inhibited proliferation of head and neck squamous cell carcinoma cells overexpressing AXL in culture (PMID: 32439698). 32439698
AXL over exp head and neck squamous cell carcinoma sensitive Cetuximab + Imatinib Preclinical - Cell line xenograft Actionable In a preclinical study, Gleevec (imatinib) treatment in combination with Erbitux (cetuximab) synergistically inhibited tumor growth and induced regression in an Erbitux (cetuximab)-resistant cell line xenograft model of head and neck squamous cell carcinoma overexpressing AXL (PMID: 32439698). 32439698
AXL over exp melanoma sensitive Bemcentinib Preclinical - Cell culture Actionable In a preclinical study, Bemcentinib (BGB-324) treatment inhibited viability of a BRAF wild-type melanoma cell line overexpressing Axl in culture (PMID: 35332208). 35332208
EML4 - ALK AXL over exp lung adenocarcinoma predicted - sensitive Bemcentinib + Crizotinib Preclinical - Cell culture Actionable In a preclinical study, Bemcentinib (BGB-324) and Xalkori (crizotinib) combination treatment did not induce apoptosis, however, inhibited proliferation of Xalkori (crizotinib)-resistant lung adenocarcinoma cells harboring EML4-ALK and overexpressing AXL in culture (PMID: 32558295). 32558295
EML4 - ALK AXL over exp lung adenocarcinoma no benefit Bemcentinib Preclinical - Cell culture Actionable In a preclinical study, Xalkori (crizotinib)-resistant lung adenocarcinoma cells harboring EML4-ALK and overexpressing AXL did not demonstrate sensitivity to Bemcentinib (BGB-324) treatment in culture (PMID: 32558295). 32558295
EML4 - ALK AXL over exp lung non-small cell carcinoma resistant Alectinib Preclinical - Cell line xenograft Actionable In a preclinical study, Alecensa (alectinib) failed to inhibit cell growth, phosphorylation of Alk and Axl, or downstream signaling in a non-small cell lung cancer cell line harboring EML4-ALK and overexpressing AXL in culture, and did not inhibit tumor growth in cell line xenograft models (PMID: 33627640). 33627640
EML4 - ALK AXL over exp lung non-small cell carcinoma sensitive Gilteritinib Preclinical - Cell line xenograft Actionable In a preclinical study, Xospata (gilteritinib) inhibited cell growth, phosphorylation of Alk and Axl, and downstream signaling in a non-small cell lung cancer cell line harboring EML4-ALK and overexpressing AXL in culture and suppressed tumor growth in cell line xenograft models and inhibited tumor growth when administered to separate xenograft models that had previously demonstrated resistance to Alecensa (alectinib) treatment (PMID: 33627640). 33627640
AXL over exp BRAF V600E melanoma sensitive Bemcentinib + Vemurafenib Preclinical - Cell line xenograft Actionable In a preclinical study, Bemcentinib (BGB-324) and Zelboraf (vemurafenib) combination treatment synergistically inhibited viability of melanoma cell lines harboring BRAF V600E and overexpressing Axl in culture, and resulted in improved tumor growth inhibition and tumor regression over either agent alone in a cell line xenograft model (PMID: 35332208). 35332208
AXL positive Ewing sarcoma sensitive Bemcentinib Preclinical - Cell culture Actionable In a preclinical study, Bemcentinib (BGB-324) inhibited growth of Ewing sarcoma cell lines positive for Axl expression in culture (PMID: 25528764). 25528764
AXL positive head and neck squamous cell carcinoma sensitive Bemcentinib Preclinical Actionable In a preclinical study, Bemcentinib (BGB-324) inhibited proliferation and invasion of head and neck squamous cell carcinoma cell lines positive for Axl expression in culture (PMID: 25767293). 25767293
AXL positive head and neck squamous cell carcinoma sensitive Bemcentinib + Cetuximab Preclinical Actionable In a preclinical study, BGB-324 and Erbitux (cetuximab) worked synergistically to inhibit proliferation of Axl-positive head and neck squamous cell carcinoma cell lines in culture (PMID: 25767293). 25767293
AXL positive breast cancer sensitive Bemcentinib Preclinical Actionable In a preclinical study, Bemcentinib (BGB-324) inhibited tumor growth and metastasis in xenograft models of Axl-positive breast cancer cell lines, resulting in prolonged survival (PMID: 20145120). 20145120
AXL positive triple-receptor negative breast cancer sensitive Dubermatinib + Olaparib Preclinical - Cell culture Actionable In a preclinical study, a triple-receptor negative breast cancer cell line expressing AXL demonstrated greater sensitivity to the combination of Dubermatinib (TP-0903) and Lynparza (olaparib) compared to either agent alone in culture, resulting in decreased colony formation, inhibition of cell growth, and increased apoptotic activity (PMID: 27671334). 27671334
AXL positive lung non-small cell carcinoma sensitive Dubermatinib + Olaparib Preclinical - Cell culture Actionable In a preclinical study, a non-small cell lung carcinoma cell line expressing AXL demonstrated greater sensitivity to the combination of Dubermatinib (TP-0903) and Lynparza (olaparib) compared to either agent alone in culture, resulting in decreased colony formation, inhibition of cell growth, and increased apoptotic activity (PMID: 27671334). 27671334
AXL positive head and neck squamous cell carcinoma sensitive Dubermatinib + Olaparib Preclinical - Cell culture Actionable In a preclinical study, a head and neck squamous cell carcinoma cell line expressing AXL demonstrated greater sensitivity to the combination of Dubermatinib (TP-0903) and Lynparza (olaparib) compared to either agent alone in culture, resulting in decreased colony formation, inhibition of cell growth, and increased apoptotic activity (PMID: 27671334). 27671334
AXL positive triple-receptor negative breast cancer sensitive Bemcentinib + Olaparib Preclinical - Cell culture Actionable In a preclinical study, an AXL-expressing triple-receptor negative breast cancer cell line demonstrated greater sensitivity to the combination of Bemcentinib (BGB-324) and Lynparza (olaparib) compared to either agent alone in culture, resulting in a highly synergistic effect (PMID: 27671334). 27671334
AXL positive lung non-small cell carcinoma sensitive Bemcentinib + Olaparib Preclinical - Cell culture Actionable In a preclinical study, an AXL-expressing non-small cell lung carcinoma cell line demonstrated greater sensitivity to the combination of BGB-324 and Lynparza (olaparib) compared to either agent alone in culture, resulting in a highly synergistic effect (PMID: 27671334). 27671334
AXL positive glioblastoma sensitive BMS-777607 Preclinical - Cell line xenograft Actionable In a preclinical study, BMS-777607 inhibited Axl phosphorylation, resulted in decreased viability of glioblastoma multiforme cell lines in culture and in cell line xenograft models (PMID: 26848524). 26848524
AXL positive acute myeloid leukemia sensitive Bemcentinib Phase I Actionable In a Phase I trial, Bemcentinib (BGB-324) treatment inhibited Axl phosphorylation, resulted in complete response in 12.5% (1/8), partial response in 12.5% (1/8), and stable disease in 37.5% (3/8) of acute myeloid leukemia patients (J Clin Oncol 34, 2016 (suppl; abstr 2561)). detail...
AXL positive myelodysplastic syndrome sensitive Bemcentinib Phase I Actionable In a Phase I trial, Bemcentinib (BGB-324) treatment inhibited Axl phosphorylation, resulted in stable disease in 100% (3/3) of myelodysplastic syndrome patients (J Clin Oncol 34, 2016 (suppl; abstr 2561)). detail...
AXL positive Advanced Solid Tumor predicted - sensitive Enapotamab vedotin Preclinical - Pdx Actionable In a preclinical study, Enapotamab vedotin (HuMax-Axl-ADC) inhibited tumor growth in solid tumor xenograft models, including induction of tumor regression in solid tumor patient-derived xenograft (PDX) models expressing Axl in a subset of tumor cells (J Clin Onc 2015 33:15_suppl, 3066). detail...
AXL positive triple-receptor negative breast cancer sensitive 20G7-D9 Preclinical - Pdx Actionable In a preclinical study, 20G7-D9 inhibited tumor growth in triple-negative breast cancer cell line xenograft models with high or moderate AXL expression and in AXL-expressing patient-derived xenograft (PDX) models (PMID: 27923843). 27923843
AXL positive chronic myeloid leukemia sensitive AXL CAR-T cells Preclinical - Cell culture Actionable In a preclinical study, treatment with AXL CAR-T cells led to induced death of AXL-expressing chronic myeloid leukemia (CML) cells and did not induce death of AXL-negative CML cells in culture (PMID: 29497107). 29497107
AXL positive lung non-small cell carcinoma unknown INCB081776 Preclinical - Cell line xenograft Actionable In a preclinical study, INCB081776 inhibited Axl phosphorylation in tumor, enhanced anti-tumor immune response, inhibited tumor growth in immunocompetent, but not immunodeficient mouse models of non-small cell lung cancer (Cancer Res 2018;78(13 Suppl):Abstract nr 3759). detail...
AXL positive triple-receptor negative breast cancer sensitive ADCT-601 Preclinical - Cell line xenograft Actionable In a preclinical study, ADCT-601 treatment inhibited growth of an AXL-positive triple-negative breast cancer cell line in culture and resulted in complete responses in 4/10, partial responses in 5/10, and tumor-free survival in 4/10 cell line xenograft models (PMID: 35086955). 35086955
AXL positive renal cell carcinoma sensitive ADCT-601 Preclinical - Cell line xenograft Actionable In a preclinical study, treatment with ADCT-601 induced DNA interstrand crosslinking and inhibited growth of an AXL-positive renal cell carcinoma cell line in culture and at the highest tested dose resulted in a partial response in 1/8, complete responses in 7/8, and tumor-free survival in 6/8 cell line xenograft models (PMID: 35086955). 35086955
AXL positive pancreatic cancer sensitive ADCT-601 Preclinical - Pdx Actionable In a preclinical study, ADCT-601 inhibited growth of an AXL-positive pancreatic cancer cell line in culture and inhibited tumor growth in a patient-derived xenograft (PDX) model (PMID: 35086955). 35086955
AXL positive esophageal cancer sensitive ADCT-601 Preclinical - Pdx Actionable In a preclinical study, ADCT-601 treatment inhibited growth of an AXL-positive esophageal cancer cell line in culture and resulted in complete responses in 2/8, partial responses in 5/8, and tumor-free survival in 2/8 patient-derived xenograft (PDX) models (PMID: 35086955). 35086955
AXL positive glioblastoma sensitive ADCT-601 Preclinical - Cell culture Actionable In a preclinical study, ADCT-601 inhibited growth of an AXL-positive glioblastoma cell line in culture (PMID: 35086955). 35086955
AXL positive lung adenocarcinoma sensitive ADCT-601 Preclinical - Cell culture Actionable In a preclinical study, ADCT-601 inhibited growth of an AXL-positive lung adenocarcinoma cell line in culture (PMID: 35086955). 35086955
AXL positive ovary adenocarcinoma sensitive ADCT-601 Preclinical - Cell culture Actionable In a preclinical study, ADCT-601 inhibited growth of an AXL-positive ovarian adenocarcinoma cell line in culture (PMID: 35086955). 35086955
AXL positive lung non-small cell carcinoma sensitive ADCT-601 Preclinical - Cell line xenograft Actionable In a preclinical study, ADCT-601 inhibited growth of an AXL-positive non-small cell lung cancer cell line in culture and inhibited tumor growth and increased survival in a cell line xenograft model (PMID: 35086955). 35086955
AXL pos TYRO3 over exp chronic lymphocytic leukemia sensitive Dubermatinib Preclinical Actionable In a preclinical study, Dubermatinib (TP-0903) inhibited survival and induced apoptosis in Axl-positive and Tyro3-over expressing B-cells derived from chronic lymphocytic leukemia patients (PMID: 25673699). 25673699
ALK R1275Q AXL pos neuroblastoma sensitive Bemcentinib + Ceritinib Preclinical - Cell culture Actionable In a preclinical study, the addition of Bemcentinib (BGB-324) to treatment with Zykadia (ceritinib) increased Zykadia (ceritinib)-induced apoptosis in an AXL-expressing neuroblastoma cell line harboring ALK R1275Q in culture (PMID: 25450694). 25450694
ALK R1275Q AXL pos neuroblastoma sensitive Bemcentinib + Crizotinib Preclinical - Cell line xenograft Actionable In a preclinical study, the addition of Bemcentinib (BGB-324) to Xalkori (crizotinib) treatment increased Xalkori (crizotinib)-induced apoptosis in an AXL-expressing neuroblastoma cell line harboring ALK R1275Q in culture, and improved efficacy in xenograft models (PMID: 25450694). 25450694
ALK F1174L AXL pos neuroblastoma sensitive Bemcentinib + Ceritinib Preclinical - Cell culture Actionable In a preclinical study, the addition of Bemcentinib (BGB-324) to treatment with Zykadia (ceritinib) increased Zykadia (ceritinib)-induced apoptosis in an AXL-expressing neuroblastoma cell line harboring ALK F1174L in culture (PMID: 25450694). 25450694
ALK F1174L AXL pos neuroblastoma sensitive Bemcentinib + Crizotinib Preclinical - Cell culture Actionable In a preclinical study, the addition of Bemcentinib (BGB-324) to treatment with Xalkori (crizotinib) increased Xalkori (crizotinib)-induced apoptosis in an AXL-expressing neuroblastoma cell line harboring ALK F1147L in culture (PMID: 25450694). 25450694
AXL pos FLT3 exon 14 ins acute myeloid leukemia sensitive ONO-7475 Preclinical - Cell line xenograft Actionable In a preclinical study, ONO-7475 treatment inhibited phosphorylation of Flt3, Erk and S6, induced apoptosis and cell cycle arrest, and reduced viability of acute myeloid leukemia cell lines expressing AXL and harboring FLT3-ITD in culture, and increased median survival in a cell line xenograft model (PMID: 28912176). 28912176
AXL pos FLT3 exon 14 ins acute myeloid leukemia sensitive Cytarabine + ONO-7475 Preclinical - Cell culture Actionable In a preclinical study, ONO-7475 combined with Cytosar-U (cytarabine) treatment resulted in enhanced reduction in viability and induction of apoptosis in acute myeloid leukemia cell lines expressing AXL and harboring FLT3-ITD in culture (PMID: 28912176). 28912176
AXL Y779F head and neck squamous cell carcinoma resistant Cetuximab Preclinical - Cell culture Actionable In a preclinical study, Erbitux (cetuximab) treatment did not inhibit proliferation of head and neck squamous cell carcinoma cells expressing AXL Y779F in culture PMID: 32439698). 32439698
AXL Y821F head and neck squamous cell carcinoma sensitive Cetuximab Preclinical - Cell line xenograft Actionable In a preclinical study, Erbitux (cetuximab) treatment inhibited proliferation of head and neck squamous cell carcinoma cells expressing AXL Y821F in culture, and delayed tumor growth in a cell line xenograft model (PMID: 32439698). 32439698
AXL Y821F head and neck squamous cell carcinoma no benefit Bemcentinib + Cetuximab Preclinical - Cell culture Actionable In a preclinical study, combining Bemcentinib (BGB-324) with Erbitux (cetuximab) treatment inhibited proliferation of head and neck squamous cell carcinoma cells expressing AXL Y821F, but did not enhance inhibition compared to cells treated with Erbitux (cetuximab) alone in culture (PMID: 32439698). 32439698
AXL Y866F head and neck squamous cell carcinoma resistant Cetuximab Preclinical - Cell culture Actionable In a preclinical study, Erbitux (cetuximab) treatment did not inhibit proliferation of head and neck squamous cell carcinoma cells expressing AXL Y866F in culture PMID: 32439698). 32439698